Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Phase III Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in ≥ 55 Years Old Insomnia Patients

KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients. This is a bridging study to investigate the efficacy and safety of KI1001(Circadin®) in Korean patients.

Study Overview

• Status: Completed
• Conditions: Sleep Initiation and Maintenance Disorders
• Intervention / Treatment: Drug: Placebo KI1001; Drug: KI1001

Detailed Description

Studies throughout the world have shown that insomnia is a common complaint that occurs in 10-50% of the population depending on age, sex and country. Among the wide variety of available treatments of sleep disturbances, the most commonly prescribed hypnotics are the benzodiazepines (BZD) and non-BZD hypnotics.

However, these hypnotics were often associated with rebound, dependency, tolerance, higher risk of falls mainly in the elderly population, anterograde memory disturbances and increased risk for motor accidents the next day.

In response to the unmet clinical need for a safe and efficacious alternative treatment for primary insomnia, that in addition to treating quantitative sleep problems, would improve sleep quality and daytime functioning, a clinical development program on melatonin for the treatment of primary insomnia was initiated.

This study is conducted using a randomised, double-blind, placebo controlled parallel group design, after a single-blind placebo period. Primary insomnia patients aged over 55 will be screened for entry into the study.

After placebo run-in period, Patients will enter a 3 weeks double-blind treatment period.

Primary parameter is quality of sleep, secondary parameters are including getting to sleep, awakening from sleep, behavior following wakefulness, quality of day and night, sleep latency and quality of life.

• Study Type: Interventional
• Enrollment (Actual): 170
• Phase: Phase 3

Contacts and Locations

Study Locations

• Korea, Republic of
  • Daegu, Korea, Republic of, 700-712
    • Keimyung University, Dongsan Medical Center
  • Gwangju, Korea, Republic of, 501-757
    • Chonnam National University Hospital
  • Seoul, Korea, Republic of, 138-736
    • Asan Medical Center
  • Seoul, Korea, Republic of, 143-729
    • Konkuk University Medical Center
  • Seoul, Korea, Republic of, 134-727
    • Kyung Hee University Hospital at Gangdong
  • Seoul, Korea, Republic of, 130-709
    • St. Paul's Hospital
  • Chungcheongnam
    • Cheonan, Chungcheongnam, Korea, Republic of, 330-715
      • Dankook University Hospital
  • Gyeonggi
    • Sungnam, Gyeonggi, Korea, Republic of, 463-707
      • Seoul National University Bundang Hospital
    • Suwon, Gyeonggi, Korea, Republic of, 442-723
      • St. Vincent Hospital
  • Kangwon
    • Chuncheon, Kangwon, Korea, Republic of, 200-722
      • KangWon National University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female and aged ≥55 years
• Suffering from primary insomnia according to DSM-IV criteria and for whom this is the consultation complaint
• Good anticipated compliance
• Written informed consent to participate in the study given by the patient voluntarily
• Confirmed diagnosis of primary insomnia by sleep history questionnaire
• Established baseline pathology
• A good compliance during the two-weeks placebo run-in period defined as 70% to 130% of prescribed tablets
• Correct use of the Sleep Diary and of the LSEQ

Exclusion Criteria:

• According to DSM-IV, subjects belonging to the following groups are excluded : 780.59(breathing related sleep disorder); 307.45(circadian thyrhm sleep disorder); 307.47(dyssomnia not otherwise specified); 780.XX(sleep disorder due to a general medical condition)
• Known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists
• Known positive serology for human immunodeficiency virus (HIV) I antibodies or HIV II antibodies
• Known chronic active viral hepatitis
• Drug abuse or history or drug abuse(including alcohol)
• History of severe pathology likely to recur during or immediately after the study
• History of severe cardiac disorders
• History of severe neurological disorders or cerebral neurosurgery
• History of severe psychiatric disorders, especially psychosis and depression, sismotherapy
• depression will be assessed by the Raskin scale : a patient with a total score ≥ 6 will not be included
• anxiety will be assessed by the Covi scale : a patient with a total score ≥ 6 will not be included
• dementia will be assessed with the Mini Mental State (MMS) : a patient with a score ≤ 24 or 26 (depending on the socio-educational level of the patient) will not be included
• Neuro-psychiatric pathologies that might interfere with insomnia, patient assessment or study medication
• Use of psychotropic treatments for the past 3 months and during the study
• Use of benzodiazepines or other hypnotics during preceding two weeks (including all benzodiazepines; zopiclone, zolpidem, zaleplon, barbiturates, buspirone and hydroxyzine)
• All hypnotics or treatments used as an hypnotic are not allowed during the study
• Severe pain likely to interfere with sleep
• Other sleep disorders according to DSM-IV criteria identified by numerical ICD 9 code: breathing-related sleep disorder (780.59), circadian rhythm sleep disorder (307.45), dyssomnia not otherwise specified (307.47) and other sleep disorders (780.xx)
• Serious diseases that could interfere with patient assessment
• Organic pathologies which have not stabilised and that might interfere with sleep, patient assessment or study medication
• Intercurrent acute or chronic somatic diseases likely to interact with sleep (for example: chronic pain from any aetiology, benign prostatic hypertrophy likely to require surgery in the coming six months)
• Any concomitant documented progressive disease likely to interfere with the conduct of the study
• Any medical condition which might interfere with the completion of the study, or which would be adversely affected and thereby increasing the risk for the patient or interfering with patient assessments.
• Patients with an excessive consumption of alcohol, coffee or tea
• Patients with an irregular lifestyle or life pattern (e.g. shift workers and patients likely to be jet lagged)
• Patients with a Body Mass Index above 30 - obesity
• Patients who have taken any investigational drug within two months preceding the first dose of the study drug. Investigational drug is defined as any drug for which a marketing authorisation has not been granted in the country where the study was conducted.
• Patients receiving concomitant treatment which are not permitted
• A positive drug screen (benzodiazepines and opiates) during the initial two week placebo run-in period

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo KI1001	Drug: Placebo KI1001; Placebo KI1001 tablets
Experimental: KI1001	Drug: KI1001; Prolonged release melatonin 2mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
QOS in LSEQ	LSEQ - Leeds Sleep Evaluation Questionnaire QOS - Quality of Sleep	three weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
GTS in LSEQ	LSEQ - Leeds Sleep Evaluation Questionnaire GTS - Getting to Sleep	three weeks
QOD	Quality of day in Patient Diary	three weeks
WHO 5-welling index		three weeks
PSQI	Pittsburgh Sleep Quality Index	three weeks
AFS in LSEQ	LSEQ - Leeds Sleep Evaluation Questionnaire AFS - Awakening from Sleep	three weeks
BFW in LSEQ	LSEQ - Leeds Sleep Evaluation Questionnaire BFW - Behavior following Wakefulness	three weeks
QON	Quality of Night in Patient Diary	three weeks

Collaborators and Investigators

• Sponsor: Kuhnil Pharmaceutical Co., Ltd.
• Collaborators: Neurim Pharmaceuticals Ltd.
• Investigators: Principal Investigator: Jin-Sang Yoon, M.D., Ph.D., Chonnam National University Hospital; Principal Investigator: Jung-Hie Lee, M.D., Ph.D., KangWon National University Hospital; Principal Investigator: In-Young Yoon, M.D., Ph.D., Seoul National University Bundang Hospital; Principal Investigator: Kyu-In Jung, M.D., Ph.D., Catholic University of Korea Saint Paul's Hospital; Principal Investigator: Yong-Won Cho, M.D., Ph.D., Keimyung University Dongsan Medical Center; Principal Investigator: Jee-Hyun Kim, M.D., Ph.D., Dankook University; Principal Investigator: Seock-Hoon Chung, M.D., Ph.D., University of Ulsan College of Medicine, Asan Medical Center

Study record dates

Study Major Dates

• Study Start: March 1, 2011
• Primary Completion (Actual): March 1, 2012
• Study Completion (Actual): March 1, 2012

Study Registration Dates

• First Submitted: October 6, 2011
• First Submitted That Met QC Criteria: October 11, 2011
• First Posted (Estimate): October 12, 2011

Study Record Updates

• Last Update Posted (Estimate): April 24, 2012
• Last Update Submitted That Met QC Criteria: April 23, 2012
• Last Verified: April 1, 2012

More Information

Terms related to this study

• Keywords: primary insomnia
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Sleep Initiation and Maintenance Disorders
• Other Study ID Numbers: 10-CC-8302